Nordson’s deal for Atrion marks ‘excellent addition’, says Loop Capital

Loop Capital analyst Chris Dankert keeps a Hold rating and $255 price target on Nordson (NDSN) but notes that the company’s $800M acquisition of Atrion (ATRI) is an “excellent addition” and the type of deal that the firm hopes to continue seeing. The deal will expand Nordson’s medical solutions portfolio into clear adjacencies including fluid management for oncology, cardiovascular, and infusion applications, even if its near-term earnings accretion is somewhat weighed down by financing costs, the analyst tells investors in a research note.